Most Popular Healthcare Penny Stocks Among Hedge Funds
Although a great movie, The Wolf of Wall Street left many people thinking penny stocks are somewhat 'untouchable'.
Epirus Biopharmaceuticals Inc. (EPRS)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Camber Capital Management Stephen Dubois | 0 | $0 | 0% | |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.72 | 3,000 | $11,161.50 | 3,000 | 2015-12-21 | Filing | |
| $3.43 | 2,200 | $7,546.00 | 2,200 | 2015-12-17 | Filing | |
| $2.80 | 8,270 | $23,156.00 | 169,982 | 2015-12-16 | Filing | |
| $2.87 | 8,069 | $23,158.03 | 161,712 | 2015-12-15 | Filing | |
| $3.85 | 2,800 | $10,780.00 | 2,800 | 2015-12-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.01 | 100,000 | $500,930.00 | 1,671,400 | 2015-02-06 | Filing | |
| $4.97 | 67,316 | $334,843.25 | 1,771,400 | 2015-02-05 | Filing | |
| $4.95 | 5,684 | $28,138.64 | 1,838,716 | 2015-02-04 | Filing | |
| $4.99 | 47,000 | $234,431.30 | 1,844,400 | 2015-02-03 | Filing | |
| $6.47 | 38,516 | $249,102.23 | 1,891,400 | 2015-01-26 | Filing |
Institutional Investors' Holdings
News See All
Is Epirus Biopharmaceuticals Inc (EPRS) A Good Stock To Buy?
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this...
Epirus Biopharmaceuticals Inc (EPRS): These Two Funds Open New Positions
The days of having no fund activity in Epirus Biopharmaceuticals Inc (NASDAQ:EPRS) are over.
Hedge Fund Resource Center